Valine Pyrrolidide Improves Glucose Tolerance in Minipigs
Author Information
Author(s): Marianne Olholm Larsen, Bidda Rolin, Ulla Ribel, Michael Wilken, Carolyn F. Deacon, Ove Svendsen, Carsten F. Gotfredsen, Richard David Carr
Primary Institution: Novo Nordisk A/S
Hypothesis
Can DPPIV inhibition improve glucose tolerance in minipigs with reduced beta-cell mass?
Conclusion
DPPIV inhibitors like valine pyrrolidide may be effective in treating type 2 diabetes, even with reduced beta-cell mass.
Supporting Evidence
- Valine pyrrolidide increased levels of intact GIP and improved glucose tolerance.
- The area under the curve for glucose was reduced after treatment with valine pyrrolidide.
- Insulin levels did not significantly increase during the oral glucose tolerance test.
Takeaway
This study found that a drug helped pigs with diabetes manage their blood sugar better, even when their insulin-producing cells were low.
Methodology
The study used a model of insulin-deficient diabetes in minipigs and measured the effects of the DPPIV inhibitor valine pyrrolidide on glucose tolerance and hormone levels.
Limitations
The study was limited to a small sample size and specific animal model, which may not fully represent human diabetes.
Participant Demographics
Six male Gottingen minipigs, aged 11 to 14 months.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website